Tropical diseases encompass all diseases that occur solely, or principally, in the tropics. In practice, the term is often taken to refer to infectious diseases that thrive in hot, humid conditions, such as malaria, leishmaniasis, schistosomiasis, onchocerciasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and dengue.
Despite the increasing risks of mosquito-transmitted epidemics in the United States and Mexico, policymakers in both countries have made little effort to prevent future outbreaks, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.
Researchers from Spain have analysed the prevalence of leishmaniasis among the population of organ transplant recipients. The findings of this study, published in the journal 'PLoS Neglected Tropical Disease', confirm that the risk of developing visceral leishmaniasis ‑the most severe form of the disease which can pose life-threatening complications‑ is more than one hundred times greater in transplant patients living in areas of disease outbreak.
Chagas disease -- the third most common parasitic infection in the world -- affects approximately 7.5 million people, mostly in Latin America. To help reduce outbreaks of this disease in their countries, the United States and Mexican governments should implement a range of programs as well as fund research for the development of Chagas vaccines and treatments, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy.
Snakebite claims thousands of lives in the world's poorest communities every year but remains a 'forgotten killer,' according to a new editorial published in the British Medical Journal.
Dengue is a mosquito-borne tropical disease currently endemic in more than 10 countries. According to the World Health Organization, 390 million people are infected by dengue every year.
An international research team, headed by Joseph Vinetz, MD, professor of medicine at University of California, San Diego School of Medicine and director of the UC San Diego Center for Tropical Medicine and Travelers Health, has been awarded a 5-year, $1.89 million cooperative agreement to carry out translational research studies of leptospirosis, an infectious and sometimes fatal bacterial disease endemic in much of the world.
In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis.
The National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), has awarded James McKerrow, MD, PhD, director of the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, with a 2015 New Therapeutic Uses Award.
A new article in Clinical Investigation highlights the learnings gleaned from monitoring several complex HIV clinical trials in Africa over a 15 year period.
The team has completed two genomics studies on the tropical disease, a condition that is estimated to cause up to 30 million illnesses and over a quarter of a million deaths globally each year.
Insects, such as mosquitoes and ticks, are responsible for transmitting a range of diseases, such as malaria, chikungunya, dengue fever, and West Nile virus. The risk of contracting such illnesses is generally only considered when booking an exotic holiday. However, experts from the Emergency Response Department at Public Health England have warned that climate change could allow such vector-borne diseases to emerge closer to home.
Half a century ago, a concentrated global effort nearly wiped a disfiguring tropical disease from the face of the earth. Now, says Case Western Reserve's James W. Kazura, MD, it's time to complete the work.
In an advance that may potentially lead to new treatments for parasitic hookworms, scientists at the University of Massachusetts Medical School and Cornell University have sequenced the genome of the hookworm, Ancylostoma ceylanicum.
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
Research led by St. Jude Children's Research Hospital scientists has identified a potential target in the quest to develop a more effective treatment for leishmaniasis, a parasitic tropical disease that kills thousands and sickens more than 1 million people worldwide each year.
The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D).
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.
Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever.
Recent breakthroughs may pave the way for vaccines and new drugs for those infected by parasitic helminths. These flatworms, including tapeworms that cause hydatid diseases and neurocysticercosis, liver flukes, and blood flukes (schistosomes), infect more than 300 million people and cause approximately four million disability-adjusted life years lost due to chronic illness and death each year.
The international research & development (R&D) consortium, AfriCoLeish, formed by six research organizations from East Africa and Europe, has launched a Phase III clinical study to address the extreme difficulty in treating visceral leishmaniasis (VL) in patients who also are HIV-positive.